Kalehua Capital Management LLC Purchases Shares of 10,236,293 Gossamer Bio, Inc. $GOSS

Kalehua Capital Management LLC acquired a new position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) in the 1st quarter, Holdings Channel.com reports. The firm acquired 10,236,293 shares of the company’s stock, valued at approximately $3,363,000. Gossamer Bio comprises about 2.4% of Kalehua Capital Management LLC’s investment portfolio, making the stock its 15th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Corient Private Wealth LLC boosted its stake in Gossamer Bio by 19,123.7% in the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after purchasing an additional 3,825,879 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Gossamer Bio by 22.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock worth $82,000 after buying an additional 4,771 shares in the last quarter. AXQ Capital LP boosted its position in shares of Gossamer Bio by 36.1% in the fourth quarter. AXQ Capital LP now owns 63,117 shares of the company’s stock valued at $196,000 after acquiring an additional 16,750 shares during the period. ProShare Advisors LLC grew its stake in shares of Gossamer Bio by 39.6% in the fourth quarter. ProShare Advisors LLC now owns 45,338 shares of the company’s stock valued at $141,000 after acquiring an additional 12,863 shares in the last quarter. Finally, Eaton Financial Holdings Company LLC acquired a new position in shares of Gossamer Bio in the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GOSS. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. HC Wainwright lowered their target price on shares of Gossamer Bio from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, June 25th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.20.

Gossamer Bio Stock Performance

GOSS opened at $0.14 on Monday. The firm has a market cap of $31.92 million, a P/E ratio of -0.17 and a beta of 2.04. Gossamer Bio, Inc. has a 52-week low of $0.11 and a 52-week high of $3.87. The business’s fifty day moving average is $0.18 and its 200-day moving average is $0.81.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million. On average, research analysts predict that Gossamer Bio, Inc. will post -0.37 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.